vs
NATURES SUNSHINE PRODUCTS INC（NATR）とCOMSCORE, INC.（SCOR）の財務データ比較。上の社名をクリックして会社を切り替えられます
NATURES SUNSHINE PRODUCTS INCの直近四半期売上が大きい（$123.8M vs $93.5M、COMSCORE, INC.の約1.3倍）。NATURES SUNSHINE PRODUCTS INCの純利益率が高く（3.3% vs 3.2%、差は0.1%）。NATURES SUNSHINE PRODUCTS INCの前年同期比売上増加率が高い（4.7% vs -1.5%）。NATURES SUNSHINE PRODUCTS INCの直近四半期フリーキャッシュフローが多い（$7.6M vs $2.9M）。過去8四半期でNATURES SUNSHINE PRODUCTS INCの売上複合成長率が高い（5.6% vs 3.8%）
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
Comscoreはアメリカ合衆国に本拠を置く世界的なメディア計測・分析企業で、企業、広告代理店、ブランドマーケター、出版社に対して専門的なマーケティングデータと分析サービスを提供しています。
NATR vs SCOR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $123.8M | $93.5M |
| 純利益 | $4.1M | $3.0M |
| 粗利率 | 72.5% | 41.0% |
| 営業利益率 | 4.3% | 7.0% |
| 純利益率 | 3.3% | 3.2% |
| 売上前年比 | 4.7% | -1.5% |
| 純利益前年比 | 1379.4% | -3.7% |
| EPS（希薄化後） | $0.23 | $9.50 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $123.8M | $93.5M | ||
| Q3 25 | $128.3M | $88.9M | ||
| Q2 25 | $114.8M | $89.4M | ||
| Q1 25 | $113.2M | $85.7M | ||
| Q4 24 | $118.2M | $94.9M | ||
| Q3 24 | $114.6M | $88.5M | ||
| Q2 24 | $110.6M | $85.8M | ||
| Q1 24 | $111.0M | $86.8M |
| Q4 25 | $4.1M | $3.0M | ||
| Q3 25 | $5.3M | $453.0K | ||
| Q2 25 | $5.3M | $-9.5M | ||
| Q1 25 | $4.7M | $-4.0M | ||
| Q4 24 | $-321.0K | $3.1M | ||
| Q3 24 | $4.3M | $-60.6M | ||
| Q2 24 | $1.3M | $-1.7M | ||
| Q1 24 | $2.3M | $-1.1M |
| Q4 25 | 72.5% | 41.0% | ||
| Q3 25 | 73.3% | 40.6% | ||
| Q2 25 | 71.7% | 40.6% | ||
| Q1 25 | 72.1% | 39.6% | ||
| Q4 24 | 72.0% | 42.4% | ||
| Q3 24 | 71.3% | 41.2% | ||
| Q2 24 | 71.4% | 39.5% | ||
| Q1 24 | 71.2% | 42.3% |
| Q4 25 | 4.3% | 7.0% | ||
| Q3 25 | 7.0% | 1.9% | ||
| Q2 25 | 3.7% | -1.9% | ||
| Q1 25 | 5.4% | -2.4% | ||
| Q4 24 | 3.8% | 4.1% | ||
| Q3 24 | 4.6% | -67.4% | ||
| Q2 24 | 5.1% | -2.2% | ||
| Q1 24 | 4.2% | -2.2% |
| Q4 25 | 3.3% | 3.2% | ||
| Q3 25 | 4.2% | 0.5% | ||
| Q2 25 | 4.6% | -10.6% | ||
| Q1 25 | 4.2% | -4.7% | ||
| Q4 24 | -0.3% | 3.3% | ||
| Q3 24 | 3.8% | -68.5% | ||
| Q2 24 | 1.2% | -2.0% | ||
| Q1 24 | 2.1% | -1.2% |
| Q4 25 | $0.23 | $9.50 | ||
| Q3 25 | $0.30 | $-0.86 | ||
| Q2 25 | $0.28 | $-2.73 | ||
| Q1 25 | $0.25 | $-1.66 | ||
| Q4 24 | $-0.02 | $-0.47 | ||
| Q3 24 | $0.23 | $-12.79 | ||
| Q2 24 | $0.07 | $-1.19 | ||
| Q1 24 | $0.12 | $-1.08 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $93.9M | $23.6M |
| 総負債低いほど良い | — | $41.5M |
| 株主資本純資産 | $161.6M | $111.4M |
| 総資産 | $261.1M | $407.7M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $93.9M | $23.6M | ||
| Q3 25 | $95.6M | $26.7M | ||
| Q2 25 | $81.3M | $26.0M | ||
| Q1 25 | $86.5M | $31.0M | ||
| Q4 24 | $84.7M | $29.9M | ||
| Q3 24 | $78.7M | $20.0M | ||
| Q2 24 | $68.7M | $14.7M | ||
| Q1 24 | $77.8M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | $111.4M | ||
| Q3 25 | $166.7M | $-26.3M | ||
| Q2 25 | $163.7M | $-21.7M | ||
| Q1 25 | $167.1M | $-13.5M | ||
| Q4 24 | $161.0M | $-8.3M | ||
| Q3 24 | $162.6M | $-2.7M | ||
| Q2 24 | $156.4M | $45.8M | ||
| Q1 24 | $159.7M | $51.4M |
| Q4 25 | $261.1M | $407.7M | ||
| Q3 25 | $264.8M | $406.9M | ||
| Q2 25 | $254.9M | $415.9M | ||
| Q1 25 | $252.7M | $421.5M | ||
| Q4 24 | $240.9M | $430.2M | ||
| Q3 24 | $245.3M | $412.5M | ||
| Q2 24 | $235.8M | $474.1M | ||
| Q1 24 | $247.3M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $9.9M | $3.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $7.6M | $2.9M |
| FCFマージンFCF / 売上 | 6.1% | 3.1% |
| 設備投資強度設備投資 / 売上 | 1.9% | 0.3% |
| キャッシュ転換率営業CF / 純利益 | 2.41× | 1.07× |
| 直近12ヶ月FCF直近4四半期 | $28.8M | $21.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $9.9M | $3.2M | ||
| Q3 25 | $18.5M | $9.5M | ||
| Q2 25 | $4.3M | $932.0K | ||
| Q1 25 | $2.6M | $9.1M | ||
| Q4 24 | $12.2M | $-10.0M | ||
| Q3 24 | $9.6M | $12.5M | ||
| Q2 24 | $1.3M | $8.7M | ||
| Q1 24 | $2.2M | $6.9M |
| Q4 25 | $7.6M | $2.9M | ||
| Q3 25 | $16.8M | $9.4M | ||
| Q2 25 | $3.0M | $787.0K | ||
| Q1 25 | $1.5M | $8.7M | ||
| Q4 24 | $10.0M | $-10.3M | ||
| Q3 24 | $7.9M | $12.4M | ||
| Q2 24 | $-2.0M | $8.5M | ||
| Q1 24 | $-1.5M | $6.6M |
| Q4 25 | 6.1% | 3.1% | ||
| Q3 25 | 13.1% | 10.5% | ||
| Q2 25 | 2.6% | 0.9% | ||
| Q1 25 | 1.3% | 10.1% | ||
| Q4 24 | 8.5% | -10.8% | ||
| Q3 24 | 6.9% | 14.0% | ||
| Q2 24 | -1.9% | 10.0% | ||
| Q1 24 | -1.4% | 7.6% |
| Q4 25 | 1.9% | 0.3% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 1.0% | 0.4% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.5% | 0.1% | ||
| Q2 24 | 3.0% | 0.2% | ||
| Q1 24 | 3.3% | 0.3% |
| Q4 25 | 2.41× | 1.07× | ||
| Q3 25 | 3.46× | 20.96× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
